A recent study showed that the clinical features of experimental atopic dermatitis are driven by IL-4 and IL-13 signaling via IL-4R and highlighted that IL-4R might serve as a potent therapeutic target for the treatment of AD and other allergic diseases [45]. This evidence concerns the gene IL13 and allergic disease.